Lonza Group AG Stock price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:30:23 2024-02-23 EST 5-day change 1st Jan Change
463.6 CHF +0.91% Intraday chart for Lonza Group AG +1.13% +31.07%

Financials

Sales 2023 6.72B 7.62B 10.29B Sales 2024 * 6.59B 7.48B 10.1B Capitalization 34.12B 38.7B 52.27B
Net income 2023 654M 742M 1B Net income 2024 * 876M 994M 1.34B EV / Sales 2023 4.05 x
Net Debt 2023 922M 1.05B 1.41B Net Debt 2024 * 2.28B 2.58B 3.49B EV / Sales 2024 * 5.52 x
P/E ratio 2023
39.8 x
P/E ratio 2024 *
37.7 x
Employees 18,000
Yield 2023
1.13%
Yield 2024 *
0.99%
Free-Float 96.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.94%
1 week+1.49%
Current month+9.20%
1 month+24.14%
3 months+31.90%
6 months-3.35%
Current year+31.16%
More quotes
1 week
447.50
Extreme 447.5
464.90
1 month
370.30
Extreme 370.3
466.00
Current year
339.00
Extreme 339
466.00
1 year
308.60
Extreme 308.6
599.40
3 years
308.60
Extreme 308.6
785.40
5 years
276.50
Extreme 276.5
785.40
10 years
81.25
Extreme 81.25
785.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 17-04-24
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Date Price Change Volume
24-02-23 463.6 +0.91% 146 076
24-02-22 459.4 +1.23% 175,186
24-02-21 453.8 -0.11% 111,821
24-02-20 454.3 -0.37% 135,336
24-02-19 456 -0.24% 161,915

Delayed Quote Swiss Exchange, February 23, 2024 at 11:11 am

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
459.4 CHF
Average target price
508.2 CHF
Spread / Average Target
+10.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Lonza Group AG - Swiss Exchange
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer